Figure 4

Effects of Selectikine on regulatory CD4⁺T-cells. (A) Frequency (%) of CD4⁺ Treg cells based on Foxp3 and CD25 expression. Dot plot representations of Foxp3 versus CD25 staining on days 1 and 8 during the first treatment cycle; and Foxp3 versus CD127 on day 8. Graphs represent individual values of 39 treated patients. Bars represent the geometric mean with 95% CI. (B) Absolute counts (Cells/mm3) of Treg cells (Foxp3⁺CD25⁺CD4⁺CD3⁺) and CD4⁺ non-Treg cells (Foxp3^-CD25^-CD4⁺CD3⁺) on days 1 and 8 during the first and second treatment cycles. Box-and-whiskers graphs show geometric mean with 95% CI. (C) Serum concentrations (pg/mL) of IL-10 measured on days 1 and 3 after Selectikine infusion in 39 treated patients in patient group 1. (D) Ki67, CD8⁺, CD4⁺ and Foxp3 immunoperoxydase staining in tumor tissue before the study (PRE-treatment), and after the second treatment cycle (POST-treatment) from melanoma patient N° 101 1102 treated with 0.225 mg/kg Selectikine. **P ≤ 0.01, ***P ≤ 0.005.